{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:14:19Z","timestamp":1793297659545,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL153712"],"award-info":[{"award-number":["R01HL153712"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL165258"],"award-info":[{"award-number":["R01HL165258"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R35HL135799"],"award-info":[{"award-number":["R35HL135799"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL084312"],"award-info":[{"award-number":["R01HL084312"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["20SFRN35210252"],"award-info":[{"award-number":["20SFRN35210252"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["20SFRN35210252"],"award-info":[{"award-number":["20SFRN35210252"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["965509"],"award-info":[{"award-number":["965509"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["23POST1029885"],"award-info":[{"award-number":["23POST1029885"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["20SFRN35210252"],"award-info":[{"award-number":["20SFRN35210252"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["20SFRN35210252"],"award-info":[{"award-number":["20SFRN35210252"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["20SFRN35210252"],"award-info":[{"award-number":["20SFRN35210252"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cardiovasc Res"],"DOI":"10.1038\/s44161-024-00563-4","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T05:02:19Z","timestamp":1732856539000},"page":"1482-1502","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4764-5503","authenticated-orcid":false,"given":"Jos\u00e9 Gabriel","family":"Barcia Dur\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayasagar","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gildea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1125-4631","authenticated-orcid":false,"given":"Letizia","family":"Amadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Gourvest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1278-2516","authenticated-orcid":false,"given":"Ravneet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3309-4563","authenticated-orcid":false,"given":"Natalia","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Smyrnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Cilhoroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathy","family":"Sajja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7675-9596","authenticated-orcid":false,"given":"Karishma","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn M.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Faries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet","family":"Narula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8049-4829","authenticated-orcid":false,"given":"Rami","family":"Vanguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8701-2201","authenticated-orcid":false,"given":"Ira J.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9802-143X","authenticated-orcid":false,"given":"Edward A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2505-2547","authenticated-orcid":false,"given":"Kathryn J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2473-6058","authenticated-orcid":false,"given":"Chiara","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"563_CR1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jacc.2021.11.048","volume":"79","author":"JT Vuong","year":"2022","unstructured":"Vuong, J. T. et al. Immune checkpoint therapies and atherosclerosis: mechanisms and clinical implications: JACC state-of-the-art review. J. Am. Coll. Cardiol. 79, 577\u2013593 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"563_CR2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24\u201334 (2022).","journal-title":"N. Engl. J. Med."},{"key":"563_CR3","doi-asserted-by":"publisher","unstructured":"FDA approves anti-LAG3 checkpoint. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-022-01331-0 (2022).","DOI":"10.1038\/s41587-022-01331-0"},{"key":"563_CR4","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam, A. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw. Open 2, e192535 (2019).","journal-title":"JAMA Netw. Open"},{"key":"563_CR5","unstructured":"US FDA. FDA Drug Database https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm (2023)."},{"key":"563_CR6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","volume":"3","author":"L Zhang","year":"2021","unstructured":"Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N. & Neilan, T. G. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: cardiooncology primer. JACC CardioOncol. 3, 35\u201347 (2021).","journal-title":"JACC CardioOncol"},{"key":"563_CR7","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaccao.2022.11.011","volume":"4","author":"GA Suero-Abreu","year":"2022","unstructured":"Suero-Abreu, G. A., Zanni, M. V. & Neilan, T. G. Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: cardiooncology state-of-the-art review. JACC CardioOncol. 4, 598\u2013615 (2022).","journal-title":"JACC CardioOncol."},{"key":"563_CR8","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni, Z. D. et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 142, 2299\u20132311 (2020).","journal-title":"Circulation"},{"key":"563_CR9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann, J. et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur. Heart J. 43, 280\u2013299 (2022).","journal-title":"Eur. Heart J."},{"key":"563_CR10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","volume":"2","author":"K Poels","year":"2020","unstructured":"Poels, K. et al. Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis. JACC CardioOncol. 2, 599\u2013610 (2020).","journal-title":"JACC CardioOncol"},{"key":"563_CR11","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","volume":"31","author":"DX Bu","year":"2011","unstructured":"Bu, D. X. et al. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler. Thromb. Vasc. Biol. 31, 1100\u20131107 (2011).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"563_CR12","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","volume":"25","author":"DM Fernandez","year":"2019","unstructured":"Fernandez, D. M. et al. Single-cell immune landscape of human atherosclerotic plaques. Nat. Med. 25, 1576\u20131588 (2019).","journal-title":"Nat. Med."},{"key":"563_CR13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jaccao.2022.09.005","volume":"4","author":"M Mulholland","year":"2022","unstructured":"Mulholland, M. et al. LAG3 regulates T cell activation and plaque infiltration in atherosclerotic mice. JACC CardioOncol. 4, 635\u2013645 (2022).","journal-title":"JACC CardioOncol"},{"key":"563_CR14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2022.11.014","volume":"363","author":"F Krautter","year":"2022","unstructured":"Krautter, F. et al. Galectin-9: a novel promoter of atherosclerosis progression. Atherosclerosis 363, 57\u201368 (2022).","journal-title":"Atherosclerosis"},{"key":"563_CR15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJMc2029834","volume":"384","author":"KU Jarr","year":"2021","unstructured":"Jarr, K. U. et al. Effect of CD47 blockade on vascular inflammation. N. Engl. J. Med. 384, 382\u2013383 (2021).","journal-title":"N. Engl. J. Med."},{"key":"563_CR16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nature18935","volume":"536","author":"Y Kojima","year":"2016","unstructured":"Kojima, Y. et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536, 86\u201390 (2016).","journal-title":"Nature"},{"key":"563_CR17","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.jacc.2023.08.015","volume":"82","author":"C Gyldenkerne","year":"2023","unstructured":"Gyldenkerne, C. et al. 10-year cardiovascular risk in patients with newly diagnosed type 2 diabetes mellitus. J. Am. Coll. Cardiol. 82, 1583\u20131594 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"563_CR18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s44161-023-00218-w","volume":"2","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Pairing of single-cell RNA analysis and T cell antigen receptor profiling indicates breakdown of T cell tolerance checkpoints in atherosclerosis. Nat. Cardiovasc. Res. 2, 290\u2013306 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"563_CR19","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s44161-023-00295-x","volume":"2","author":"L Dib","year":"2023","unstructured":"Dib, L. et al. Lipid-associated macrophages transition to an inflammatory state in human atherosclerosis, increasing the risk of cerebrovascular complications. Nat. Cardiovas. Res. 2, 656\u2013672 (2023).","journal-title":"Nat. Cardiovas. Res."},{"key":"563_CR20","doi-asserted-by":"publisher","unstructured":"Slysz, J. et al. Single-cell profiling reveals comparatively inflammatory polarization of human carotid versus femoral plaque leukocytes. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.171359 (2023).","DOI":"10.1172\/jci.insight.171359"},{"key":"563_CR21","doi-asserted-by":"crossref","DOI":"10.1126\/science.abl5197","volume":"376","author":"C Dominguez Conde","year":"2022","unstructured":"Dominguez Conde, C. et al. Cross-tissue immune cell analysis reveals tissue-specific features in humans. Science 376, eabl5197 (2022).","journal-title":"Science"},{"key":"563_CR22","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9306","volume":"6","author":"JP Bottcher","year":"2015","unstructured":"Bottcher, J. P. et al. Functional classification of memory CD8(+) T cells by CX3CR1 expression. Nat. Commun. 6, 8306 (2015).","journal-title":"Nat. Commun."},{"key":"563_CR23","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1161\/CIRCRESAHA.120.316770","volume":"127","author":"MAC Depuydt","year":"2020","unstructured":"Depuydt, M. A. C. et al. Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics. Circ. Res. 127, 1437\u20131455 (2020).","journal-title":"Circ. Res."},{"key":"563_CR24","first-page":"4472","volume":"7","author":"CH June","year":"1987","unstructured":"June, C. H., Ledbetter, J. A., Gillespie, M. M., Lindsten, T. & Thompson, C. B. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol. Cell. Biol. 7, 4472\u20134481 (1987).","journal-title":"Mol. Cell. Biol."},{"key":"563_CR25","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","volume":"174","author":"PS Linsley","year":"1991","unstructured":"Linsley, P. S. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561\u2013569 (1991).","journal-title":"J. Exp. Med."},{"key":"563_CR26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-3-030-35582-1_8","volume":"1223","author":"JQ Liu","year":"2020","unstructured":"Liu, J. Q. et al. CD200-CD200R pathway in the regulation of tumor immune microenvironment and immunotherapy. Adv. Exp. Med. Biol. 1223, 155\u2013165 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"563_CR27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1161\/CIRCRESAHA.119.316062","volume":"129","author":"C Kassiteridi","year":"2021","unstructured":"Kassiteridi, C. et al. CD200 limits monopoiesis and monocyte recruitment in atherosclerosis. Circ. Res. 129, 280\u2013295 (2021).","journal-title":"Circ. Res."},{"key":"563_CR28","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1093\/eurheartj\/ehz283","volume":"40","author":"E Lutgens","year":"2019","unstructured":"Lutgens, E. et al. Immunotherapy for cardiovascular disease. Eur. Heart J. 40, 3937\u20133946 (2019).","journal-title":"Eur. Heart J."},{"key":"563_CR29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nature14189","volume":"517","author":"D Artis","year":"2015","unstructured":"Artis, D. & Spits, H. The biology of innate lymphoid cells. Nature 517, 293\u2013301 (2015).","journal-title":"Nature"},{"key":"563_CR30","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1093\/eurheartj\/ehaa484","volume":"41","author":"A Shami","year":"2020","unstructured":"Shami, A. et al. Glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) drives atherosclerosis in mice and is associated with an unstable plaque phenotype and cerebrovascular events in humans. Eur. Heart J. 41, 2938\u20132948 (2020).","journal-title":"Eur. Heart J."},{"key":"563_CR31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23909-z","volume":"12","author":"M Lacy","year":"2021","unstructured":"Lacy, M. et al. Cell-specific and divergent roles of the CD40L\u2013CD40 axis in atherosclerotic vascular disease. Nat. Commun. 12, 3754 (2021).","journal-title":"Nat. Commun."},{"key":"563_CR32","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.CIR.92.5.1355","volume":"92","author":"HC Stary","year":"1995","unstructured":"Stary, H. C. et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 92, 1355\u20131374 (1995).","journal-title":"Circulation"},{"key":"563_CR33","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231263","volume":"221","author":"N Sharma","year":"2024","unstructured":"Sharma, N. et al. ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype. J. Exp. Med. 221, e20231263 (2024).","journal-title":"J. Exp. Med."},{"key":"563_CR34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/path.6197","volume":"261","author":"RS Vanguri","year":"2023","unstructured":"Vanguri, R. S. et al. Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma. J. Pathol. 261, 349\u2013360 (2023).","journal-title":"J. Pathol."},{"key":"563_CR35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejca.2023.03.014","volume":"187","author":"D Schadendorf","year":"2023","unstructured":"Schadendorf, D. et al. Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. Eur. J. Cancer 187, 164\u2013173 (2023).","journal-title":"Eur. J. Cancer"},{"key":"563_CR36","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/1078-0432.CCR-19-2095","volume":"26","author":"L Borst","year":"2020","unstructured":"Borst, L., van der Burg, S. H. & van Hall, T. The NKG2A\u2013HLA-E axis as a novel checkpoint in the tumor microenvironment. Clin. Cancer Res. 26, 5549\u20135556 (2020).","journal-title":"Clin. Cancer Res."},{"key":"563_CR37","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1161\/ATVBAHA.113.301879","volume":"33","author":"AC Foks","year":"2013","unstructured":"Foks, A. C. et al. T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 33, 2558\u20132565 (2013).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"563_CR38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.580557","volume":"11","author":"IM Yasinska","year":"2020","unstructured":"Yasinska, I. M. et al. Ligand\u2013receptor interactions of galectin-9 and VISTA suppress human T lymphocyte cytotoxic activity. Front. Immunol. 11, 580557 (2020).","journal-title":"Front. Immunol."},{"key":"563_CR39","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang, R. et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat. Commun. 12, 832 (2021).","journal-title":"Nat. Commun."},{"key":"563_CR40","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ni1144","volume":"6","author":"JR Sedy","year":"2005","unstructured":"Sedy, J. R. et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat. Immunol. 6, 90\u201398 (2005).","journal-title":"Nat. Immunol."},{"key":"563_CR41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s13046-021-02068-5","volume":"40","author":"B Wu","year":"2021","unstructured":"Wu, B. et al. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy. J. Exp. Clin. Cancer Res. 40, 267 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"563_CR42","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","volume":"41","author":"PH O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell, P. H. et al. Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer. J. Clin. Oncol. 41, 4107\u20134117 (2023). JCO2202887.","journal-title":"J. Clin. Oncol."},{"key":"563_CR43","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ni.2085","volume":"12","author":"A Braun","year":"2011","unstructured":"Braun, A. et al. Afferent lymph-derived T cells and DCs use different chemokine receptor CCR7-dependent routes for entry into the lymph node and intranodal migration. Nat. Immunol. 12, 879\u2013887 (2011).","journal-title":"Nat. Immunol."},{"key":"563_CR44","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.4049\/jimmunol.1001667","volume":"186","author":"Y Yamakita","year":"2011","unstructured":"Yamakita, Y. et al. Fascin1 promotes cell migration of mature dendritic cells. J. Immunol. 186, 2850\u20132859 (2011).","journal-title":"J. Immunol."},{"key":"563_CR45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","volume":"580","author":"B Maier","year":"2020","unstructured":"Maier, B. et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature 580, 257\u2013262 (2020).","journal-title":"Nature"},{"key":"563_CR46","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","volume":"29","author":"A Magen","year":"2023","unstructured":"Magen, A. et al. Intratumoral dendritic cell-CD4(+) T helper cell niches enable CD8(+) T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat. Med. 29, 1389\u20131399 (2023).","journal-title":"Nat. Med."},{"key":"563_CR47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.medj.2023.04.008","volume":"4","author":"SY Wu","year":"2023","unstructured":"Wu, S. Y. et al. CCL19(+) dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. Medicine 4, 373\u2013393 e378 (2023).","journal-title":"Medicine"},{"key":"563_CR48","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby, P. The changing landscape of atherosclerosis. Nature 592, 524\u2013533 (2021).","journal-title":"Nature"},{"key":"563_CR49","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","volume":"367","author":"SF Nielsen","year":"2012","unstructured":"Nielsen, S. F., Nordestgaard, B. G. & Bojesen, S. E. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367, 1792\u20131802 (2012).","journal-title":"N. Engl. J. Med."},{"key":"563_CR50","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/CIRCRESAHA.119.316461","volume":"127","author":"M Sharma","year":"2020","unstructured":"Sharma, M. et al. Regulatory T cells license macrophage pro-resolving functions during atherosclerosis regression. Circ. Res. 127, 335\u2013353 (2020).","journal-title":"Circ. Res."},{"key":"563_CR51","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCRESAHA.121.319313","volume":"129","author":"M Schlegel","year":"2021","unstructured":"Schlegel, M. et al. Silencing myeloid netrin-1 induces inflammation resolution and plaque regression. Circ. Res. 129, 530\u2013546 (2021).","journal-title":"Circ. Res."},{"key":"563_CR52","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1161\/CIRCRESAHA.120.317914","volume":"128","author":"MS Afonso","year":"2021","unstructured":"Afonso, M. S. et al. miR-33 silencing reprograms the immune cell landscape in atherosclerotic plaques. Circ. Res. 128, 1122\u20131138 (2021).","journal-title":"Circ. Res."},{"key":"563_CR53","volume":"121","author":"Y Cyr","year":"2024","unstructured":"Cyr, Y. et al. The IRG1\u2013itaconate axis protects from cholesterol-induced inflammation and atherosclerosis. Proc. Natl Acad. Sci. USA 121, e2400675121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"563_CR54","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/ni1008-1091","volume":"9","author":"TS Heng","year":"2008","unstructured":"Heng, T. S., Painter, M. W. & Immunological Genome Project. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9, 1091\u20131094 (2008).","journal-title":"Nat. Immunol."},{"key":"563_CR55","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1161\/ATVBAHA.120.314252","volume":"40","author":"K Di Gregoli","year":"2020","unstructured":"Di Gregoli, K. et al. Galectin-3 identifies a subset of macrophages with a potential beneficial role in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 40, 1491\u20131509 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"563_CR56","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","volume":"50","author":"MT Chow","year":"2019","unstructured":"Chow, M. T. et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity 50, 1498\u20131512 e1495 (2019).","journal-title":"Immunity"},{"key":"563_CR57","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.4049\/jimmunol.157.11.4762","volume":"157","author":"ML Alegre","year":"1996","unstructured":"Alegre, M. L. et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol. 157, 4762\u20134770 (1996).","journal-title":"J. Immunol."},{"key":"563_CR58","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10018-1","volume":"10","author":"KL Truong","year":"2019","unstructured":"Truong, K. L. et al. Killer-like receptors and GPR56 progressive expression defines cytokine production of human CD4(+) memory T cells. Nat. Commun. 10, 2263 (2019).","journal-title":"Nat. Commun."},{"key":"563_CR59","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1084\/jem.20070663","volume":"204","author":"F Annunziato","year":"2007","unstructured":"Annunziato, F. et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204, 1849\u20131861 (2007).","journal-title":"J. Exp. Med."},{"key":"563_CR60","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","volume":"317","author":"JR Groom","year":"2011","unstructured":"Groom, J. R. & Luster, A. D. CXCR3 in T cell function. Exp. Cell. Res. 317, 620\u2013631 (2011).","journal-title":"Exp. Cell. Res."},{"key":"563_CR61","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00125-022-05854-8","volume":"66","author":"S Ling","year":"2023","unstructured":"Ling, S. et al. Inequalities in cancer mortality trends in people with type 2 diabetes: 20 year population-based study in England. Diabetologia 66, 657\u2013673 (2023).","journal-title":"Diabetologia"},{"key":"563_CR62","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"563_CR63","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","volume":"122","author":"MD Shapiro","year":"2018","unstructured":"Shapiro, M. D., Tavori, H. & Fazio, S. PCSK9: from basic science discoveries to clinical trials. Circ. Res. 122, 1420\u20131438 (2018).","journal-title":"Circ. Res."},{"key":"563_CR64","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","volume":"588","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature 588, 693\u2013698 (2020).","journal-title":"Nature"},{"key":"563_CR65","volume":"13","author":"R Wang","year":"2022","unstructured":"Wang, R. et al. Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8(+) T cells and the exclusion of Treg cells. Front. Immunol. 13, 947756 (2022).","journal-title":"Front. Immunol."},{"key":"563_CR66","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3390\/cancers15051397","volume":"15","author":"V Quagliariello","year":"2023","unstructured":"Quagliariello, V. et al. PCSK9 inhibitors in cancer patients treated with immune-checkpoint inhibitors to reduce cardiovascular events: new frontiers in cardioncology. Cancers 15, 1397 (2023).","journal-title":"Cancers"},{"key":"563_CR67","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20750-8","volume":"12","author":"AT Cohain","year":"2021","unstructured":"Cohain, A. T. et al. An integrative multiomic network model links lipid metabolism to glucose regulation in coronary artery disease. Nat. Commun. 12, 547 (2021).","journal-title":"Nat. Commun."},{"key":"563_CR68","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 5, 941\u2013950 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"563_CR69","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1073\/pnas.87.13.5031","volume":"87","author":"PS Linsley","year":"1990","unstructured":"Linsley, P. S., Clark, E. A. & Ledbetter, J. A. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7\/BB-1. Proc. Natl Acad. Sci. USA 87, 5031\u20135035 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"563_CR70","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/366076a0","volume":"366","author":"M Azuma","year":"1993","unstructured":"Azuma, M. et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366, 76\u201379 (1993).","journal-title":"Nature"},{"key":"563_CR71","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu, C. et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6, 1245\u20131252 (2005).","journal-title":"Nat. Immunol."},{"key":"563_CR72","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/hep.25777","volume":"56","author":"H Li","year":"2012","unstructured":"Li, H. et al. Tim-3\/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 56, 1342\u20131351 (2012).","journal-title":"Hepatology"},{"key":"563_CR73","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-018-1603-1","volume":"19","author":"M Stoeckius","year":"2018","unstructured":"Stoeckius, M. et al. Cell hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics. Genome Biol. 19, 224 (2018).","journal-title":"Genome Biol."},{"key":"563_CR74","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s44161-023-00336-5","volume":"10","author":"N Eberhardt","year":"2023","unstructured":"Eberhardt, N. et al. SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels. Nat. Cardiovasc. Res. 10, 899\u2013916 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"563_CR75","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-019-1874-1","volume":"20","author":"C Hafemeister","year":"2019","unstructured":"Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 296 (2019).","journal-title":"Genome Biol."},{"key":"563_CR76","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25960-2","volume":"12","author":"JW Squair","year":"2021","unstructured":"Squair, J. W. et al. Confronting false discoveries in single-cell differential expression. Nat. Commun. 12, 5692 (2021).","journal-title":"Nat. Commun."},{"key":"563_CR77","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1016\/j.cell.2023.11.026","volume":"26","author":"C Xu","year":"2023","unstructured":"Xu, C. et al. Automatic cell type harmonization and integration across Human Cell Atlas datasets. Cell 26, 5876\u20135891 (2023).","journal-title":"Cell"},{"key":"563_CR78","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kr\u00e4mer","year":"2013","unstructured":"Kr\u00e4mer, A., Green, J., Pollard, J. Jr & Tugendreich, S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 30, 523\u2013530 (2013).","journal-title":"Bioinformatics"},{"key":"563_CR79","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell\u2013cell communication using CellChat. Nat. Commun. 12, 1088 (2021).","journal-title":"Nat. Commun."},{"key":"563_CR80","doi-asserted-by":"crossref","first-page":"979","DOI":"10.12688\/f1000research.73600.1","volume":"10","author":"PL Germain","year":"2021","unstructured":"Germain, P. L., Lun, A., Garcia Meixide, C., Macnair, W. & Robinson, M. D. Doublet identification in single-cell sequencing data using scDblFinder. F1000Res 10, 979 (2021).","journal-title":"F1000Res"},{"key":"563_CR81","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-019-0512-5","volume":"25","author":"RC Wirka","year":"2019","unstructured":"Wirka, R. C. et al. Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis. Nat. Med. 25, 1280\u20131289 (2019).","journal-title":"Nat. Med."},{"key":"563_CR82","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 e3529 (2021).","journal-title":"Cell"},{"key":"563_CR83","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337 e324 (2019).","journal-title":"Cell Syst."},{"key":"563_CR84","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","volume":"176","author":"H Li","year":"2019","unstructured":"Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775\u2013789 e718 (2019).","journal-title":"Cell"},{"key":"563_CR85","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41577-020-0345-y","volume":"20","author":"DG Pellicci","year":"2020","unstructured":"Pellicci, D. G., Koay, H. F. & Berzins, S. P. Thymic development of unconventional T cells: how NKT cells, MAIT cells and \u03b3\u03b4 T cells emerge. Nat. Rev. Immunol. 20, 756\u2013770 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"563_CR86","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"563_CR87","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41592-021-01358-2","volume":"19","author":"G Palla","year":"2022","unstructured":"Palla, G. et al. Squidpy: a scalable framework for spatial omics analysis. Nat. Methods 19, 171\u2013178 (2022).","journal-title":"Nat. Methods"},{"key":"563_CR88","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","volume":"20","author":"A Arazi","year":"2019","unstructured":"Arazi, A. et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat. Immunol. 20, 902\u2013914 (2019).","journal-title":"Nat. Immunol."}],"container-title":["Nature Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44161-024-00563-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-024-00563-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-024-00563-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T18:59:26Z","timestamp":1733943566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44161-024-00563-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":88,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1038\/s44161-024-00563-4","relation":{},"ISSN":["2731-0590"],"issn-type":[{"value":"2731-0590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}